| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology, Pathobiology, and Genetics |
1 Graduate School of Biomedical Sciences and 2 Department of Biochemistry, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey; and 3 Department of Pathology, Keio University School of Medicine, Tokyo, Japan
Requests for reprints: Kiran K. Chada, Department of Biochemistry, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, 675 Hoes Lane, Piscataway, NJ 08854. E-mail: chada{at}umdnj.edu.
The high-mobility group AT-hook 2 (HMGA2) protein is a member of the high-mobility group family of the DNA-binding architectural factors and participates in the conformational regulation of active chromatin on its specific downstream target genes. HMGA2 is expressed in the undifferentiated mesenchyme and is undetectable in their differentiated counterparts, suggesting its functional importance in mesenchymal cellular proliferation and differentiation. Interestingly, it is a frequent target of chromosomal translocations in several types of human benign differentiated mesenchymal tumors, including lipomas, fibroadenomas of the breast, salivary gland adenomas, and endometrial polyps. The translocations lead to a variety of HMGA2 transcripts, which range from wild-type, truncated, and fusion mRNA species. However, it is not clear whether alteration of the HMGA2 transcript is required for its tumorigenic potential. To determine whether misexpression of HMGA2 in differentiated mesenchymal cells is sufficient to cause tumorigenesis, we produced transgenic mice that misexpressed full-length or truncated human HMGA2 transcript under the control of the differentiated mesenchymal cell (adipocyte)–specific promoter of the adipocyte P2 (Fabp4) gene. Expression of the full-length HMGA2 transgene was observed in a number of tissues, which produced neoplastic phenotype, including fibroadenomas of the breast and salivary gland adenomas. Furthermore, transgenic misexpression of the truncated version of HMGA2, containing only the three DNA-binding domains, produced similar phenotypes. These results show that misexpression of HMGA2 in a differentiated mesenchymal cell is sufficient to cause mesenchymal tumorigenesis and is independent of the nature of the HMGA2 transcript that results from chromosomal translocations observed in humans. (Cancer Res 2006; 66(15): 7453-9)
This article has been cited by other articles:
|
|
 |
|
  P. S. Tanwar, H.-J. Lee, L. Zhang, L. R. Zukerberg, M. M. Taketo, B. R. Rueda, and J. M. Teixeira Constitutive Activation of Beta-Catenin in Uterine Stroma and Smooth Muscle Leads to the Development of Mesenchymal Tumors in Mice Biol Reprod, September 1, 2009; 81(3): 545 - 552. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Y.J. Li, L. M. Boo, S.-Y. Wang, H. H. Lin, C. C.C. Wang, Y. Yen, B. P.C. Chen, D. J. Chen, and D. K. Ann Suppression of Nonhomologous End Joining Repair by Overexpression of HMGA2 Cancer Res., July 15, 2009; 69(14): 5699 - 5706. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Summer, O. Li, Q. Bao, L. Zhan, S. Peter, P. Sathiyanathan, D. Henderson, T. Klonisch, S. D. Goodman, and P. Droge HMGA2 exhibits dRP/AP site cleavage activity and protects cancer cells from DNA-damage-induced cytotoxicity during chemotherapy Nucleic Acids Res., July 1, 2009; 37(13): 4371 - 4384. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kubo, M. Shimizu, Y. Taya, T. Kawamoto, M. Michida, E. Kaneko, A. Igarashi, M. Nishimura, K. Segoshi, Y. Shimazu, et al. Identification of mesenchymal stem cell (MSC)-transcription factors by microarray and knockdown analyses, and signature molecule-marked MSC in bone marrow by immunohistochemistry Genes Cells, March 1, 2009; 14(3): 407 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Di Cello, J. Hillion, A. Hristov, L. J. Wood, M. Mukherjee, A. Schuldenfrei, J. Kowalski, R. Bhattacharya, R. Ashfaq, and L. M.S. Resar HMGA2 Participates in Transformation in Human Lung Cancer Mol. Cancer Res., May 1, 2008; 6(5): 743 - 750. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Motoyama, H. Inoue, Y. Nakamura, H. Uetake, K. Sugihara, and M. Mori Clinical Significance of High Mobility Group A2 in Human Gastric Cancer and Its Relationship to let-7 MicroRNA Family Clin. Cancer Res., April 15, 2008; 14(8): 2334 - 2340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Pangas, X. Li, L. Umans, A. Zwijsen, D. Huylebroeck, C. Gutierrez, D. Wang, J. F. Martin, S. P. Jamin, R. R. Behringer, et al. Conditional Deletion of Smad1 and Smad5 in Somatic Cells of Male and Female Gonads Leads to Metastatic Tumor Development in Mice Mol. Cell. Biol., January 1, 2008; 28(1): 248 - 257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R.J. Young and M. Narita Oncogenic HMGA2: short or small? Genes & Dev., May 1, 2007; 21(9): 1005 - 1009. [Full Text] [PDF]
|
|
|
|
|
|
Y. S. Lee and A. Dutta The tumor suppressor microRNA let-7 represses the HMGA2 oncogene Genes & Dev., May 1, 2007; 21(9): 1025 - 1030. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Cattaruzzi, S. Altamura, M. A. Tessari, A. Rustighi, V. Giancotti, C. Pucillo, and G. Manfioletti The second AT-hook of the architectural transcription factor HMGA2 is determinant for nuclear localization and function Nucleic Acids Res., March 19, 2007; 35(6): 1751 - 1760. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
